CS Paper Radar

Can LLMs Reliably Annotate Bioassay Metadata to Improve Data Readiness?

Laura van Weesep, Riccardo Tedoldi, Jens Sjölund, Hossein Azizpour, Susanne Winiwarter, Ola Engkvist, Jon Paul Janet, Samuel Genheden, Juan Viguera Diez

cs.CL cs.AIcs.DBq-bio.QM ·submitted 2026-10-01 12:54 UTC · v1
publishedcode/data

Abstract

The emergence of foundation models for molecular property prediction requires a high degree of AI data readiness, including reliable metadata annotation. However, both public repositories and industrial screening databases suffer from missing, inconsistent, or conflated assay annotations. In this work, we quantify the extent of missing annotations in PubChem for the BioAssay Ontology (BAO) assay format and physical detection method fields and investigate whether open-source and proprietary large language models (LLMs) can reliably predict and audit metadata annotations directly from the assay text. In our assessment, we found that the annotation coverage across PubChem's $\sim$2 million bioassays is critically sparse, 36\% lacking an assay format, 89\% a BioAssay type, and >99.9\% any BAO-mapped assay format or detection technology term. This motivates the need for automated test-metadata curation. Using evaluation sets derived from PubChem and ChEMBL, we assess the agreement of seven open-source and proprietary LLMs with existing silver labels. Recall is at least 0.96 for biochemical and cell-based assay formats, with a similar pattern for detection technology, although disagreements increase on under-represented classes. Manual inspection shows that many of these disagreements trace back to inconsistencies between silver sources rather than to LLM error. Moreover, in a qualitative study with a senior industrial curator, LLM-generated evidence prompted the expert to revise some of their own labels, showing LLMs can flag potentially mislabeled assays. Across the study, performance differences between proprietary and open-source models were small. Together, these results suggest LLMs can support the large-scale annotation and auditing of assay metadata, though per-class reliability estimates and targeted human review remain necessary before such labels enter downstream ML pipelines.

Comment
Accepted to the AIDaR workshop at NeurIPS

Closest papers

Nearest neighbours by meaning across the whole index.

Auditing Tool Traces in Agentic LLMs: Source Localization and Counterfactual Dependence Testing

cs.AI cs.CL ·2026-10-18 ·Junhao Liu, Tianxiao Li, Yongxian Wu, Ziheng Duan, Ren Li +2 more
publishedbenchmarkhot direction similarity 0.67
Abstract · 12 pages. Accepted at the NeurIPS 2026 Workshop on Agentic AI for Biological Discovery (AgenticLS)

Agentic LLMs increasingly support scientific prediction by grounding decisions in external evidence. In biology, they promise accurate, interpretable predictions for important problems by integrating complex experimental and computational evidence. However, serialized tool results can contain hidden label shortcuts, such as dataset identifiers or template artifacts, that create apparent success without biological reasoning. To address this risk, we introduce a two-stage audit. Stage 1, Per-Tool TF-IDF Decomposition (PT2D), localizes label-predictive patterns to individual tool results while avoiding signal dilution in the concatenated tool trace. Stage 2, Token-Class Redaction, counterfactually tests whether the frozen LLM depends on the localized shortcut. We apply this audit to TCR-pMHC binding, where tool augmentation substantially outperforms a no-evidence baseline. At face value, this suggests that the LLM has learned to use scientific evidence. The audit overturns this interpretation: PT2D localizes the strongest signal to identifiers in one tool result, and redacting them reduces performance to chance. These findings show how hidden label shortcuts can masquerade as scientific reasoning or discovery, motivating source-level audits before benchmark gains are trusted.

0.38

TCMScience: An Autonomous Scientist for Traditional Chinese Medicine

cs.LG ·2026-10-17 ·Yanlan Kang, Ruiqi Liu, Xinpei Gu, Tzu-Yi Lei, Shuai Xu +2 more
code/data similarity 0.65
Abstract · 21 pages, 3 figures, including appendices. Code: https://github.com/IMPF-AI-Institute/TCMScience

Traditional Chinese medicine (TCM) research connects classical texts, medicinal entities, molecular assays, computational predictions, and clinical studies. An autonomous research agent must preserve the inferential boundaries between these evidence types while coordinating analysis across heterogeneous resources. We introduce TCMScience, a scientific knowledge-discovery agent that separates language-model proposals from execution and release authority. Its architecture combines a trusted kernel, a scientific compiler, and claim-support contracts: plans are compiled into typed operations, execution is bounded by explicit permissions, and candidate findings are checked against source provenance, study design, and claim scope before release. The full capability registry contains 117 public-source connectors with 444 typed operations across 29 domains and 150 native tools across 12 domains; the TCM data hub catalogs 136 databases, 76 dataset specifications, and 84,294 formula-source records. These resources support model-independent workflows through browser and local execution interfaces. In a network-pharmacology analysis of Gegen Qinlian Tang, replacing the whole-proteome background with the assayed-protein background changed the number of significant pathways from 66 to zero; incorporating inactive screening records identified nine pathways, including drug-metabolism signals retained as mechanistic hypotheses. A governance ablation over 121 constructed erroneous outputs spanning 26 classes released 121 errors without governance, 57 with the domain layer, seven with the kernel, and zero with both layers. All 10 compliant controls were retained. These results establish complementary control of known failure modes and show how explicit evidence contracts change the conclusions an agent is permitted to report.

0.34

Feature Selection for Tabular Foundation Models: Exploring Feature Utility in Low-Data Molecular Prediction

cs.LG ·2026-09-25 ·Yiqi Yao, Miquel Duran-Frigola
code/data similarity 0.64
Abstract · 34 pages, 13 figures, 21 tables, 11 appendices. v3: revised and expanded with held-out FS-Mol test evaluations. Code: https://github.com/ers…

Choosing features is difficult with few labeled molecules, even for a tabular foundation model that learns in context. We study this problem with TabPFN for low-data molecular property prediction, separating input width, feature meaning, and predictive usefulness while keeping contexts, query molecules, and predictor settings matched. On ADME/Tox assays from Therapeutics Data Commons, endpoint-matched assay predictions improve a compact RDKit descriptor baseline, and a provenance audit shows that most audited query molecules already occur in the predictors' training sources. Across 77 FS-Mol development tasks and 157 held-out test assays drawn from ChEMBL, broad RDKit descriptor and fingerprint families provide a strong default, rank-averaging TabPFN with support-fitted fingerprint forests improves upon both models, and learned weighting of family predictions adds further gains at a larger prediction budget. A utility-trained selector builds a traceable 16-column input from 238 sourceassay predictors, improving upon the baseline while trailing wider representations and equalwidth structural SVD coordinates. Named outputs identify what each feature predicts and where it comes from. Their usefulness for a new assay is assessed alongside the other input features, and paired removal and replacement tests measure what each selected output contributes. Together, these studies offer a protocol for evaluating feature selection, representation choice, and data provenance with a fixed tabular foundation model for few-shot molecular property prediction.

0.36

Generating Biomedical Fact-Checking Reports with RL-Enhanced Agentic Search

cs.AI ·2026-08-24 ·Jiongxiao Wang, Dingli Ma, Chaoqun Ni
code/data similarity 0.62
Abstract

Automated fact-checking is essential for ensuring the reliability of public health information, yet the biomedical domain poses unique challenges. Validating biomedical claims requires rigorous interpretation of scientific literature, assessment of retrieved evidence, and comprehensive justification toward the conclusion. Although Large Language Models (LLMs) enhanced by Retrieval-Augmented Generation (RAG) and agentic search perform automated fact-checking in a retrieve-then-verify paradigm, current methods still output isolated prediction labels, lacking explanatory depth and offers limited utility for human understanding. To bridge this gap, we introduce an LLM-based agent named BioCheck Agent that generates structured biomedical fact-checking reports with agentic search. Rather than merely outputting supported or refuted labels, our agent synthesizes final conclusions with retrieved evidence and rigorous analysis. To ensure domain-specific accuracy, BioCheck Agent exclusively searches high-quality scientific literature in PubMed, utilizing advanced Boolean search operators. Recognizing that direct prompting often results in hallucinations and low-quality reports, especially for lightweight open-source models, we further propose the Evidence-Grounded Group Relative Policy Optimization (EG-GRPO) to perform reinforcement learning on BioCheck Agent with a task-specific reward that incentivizes advanced search behavior and high-quality evidence retrieval while penalizing hallucinations. Our experimental results show that compared to the base model Qwen3.5-4B, BioCheck Agent with EG-GRPO improves label prediction accuracy on SciFact by 9.95%. Furthermore, it achieves a 3.7% higher evidence quality score and a 19.63% lower evidence hallucination rate, demonstrating its ability to generate biomedical fact-checking reports with improved accuracy and quality.

0.32

LLMCrater: Lifecycle-Aware FAIR Metadata Generation using Large Language Models

cs.SE ·2026-08-24 ·Dani Termaat, Nafiseh Soveizi, Zhiming Zhao, Marios Avgeris
published similarity 0.62
Abstract · 2 pages, 1 figure. Accepted at the 22nd IEEE International Conference on e-Science (eScience 2026)

FAIR (Findable, Accessible, Interoperable, and Reusable) metadata is essential for the discovery, interoperability, and reuse of scientific research assets. However, creating and maintaining FAIR metadata remains largely manual, making the process time-consuming for heterogeneous research artifacts generated throughout the research lifecycle. Existing approaches primarily generate metadata at publication time, missing opportunities to capture contextual information as it becomes available. To address this limitation, we present \emph{LLMCrater}, a lifecycle-aware metadata generation framework that combines Large Language Models (LLMs) with stage-specific RO-Crate metadata profiles. The framework progressively enriches metadata across four research lifecycle stages (Design, Development, Deployment, and Execution \& Provenance) while remaining compatible with RO-Crate~1.1 and EOSC metadata recommendations. It automatically extracts metadata from heterogeneous artifacts, generates and validates machine-actionable RO-Crates, and supports publication to FAIR repositories and PID services (e.g., Zenodo). We demonstrate the approach using two representative use cases: a 5G experimentation environment within SLICES-RI and an experiment on GreenDIGIT's EcoJupyter platform. Results show that LLMCrater progressively enriches metadata throughout the research lifecycle and generates valid RO-Crates conforming to the RO-Crate~1.1 specification.

0.28

Rigorous Evaluation of Large Language Models for Malaria Drug Discovery: Trade-offs in Performance, Scale, and Resource Utility

cs.AI q-bio.QMcs.LG ·2026-08-18 ·Marvellous O. Ajala, Zainab Ashimiyu-Abdusalam, Comfort Adesina
code/data similarity 0.62
Abstract · 12 pages, 4 tables, 2 figures, Ijcai2026 style

We introduce Malaria-Instruct, a curated instruction-following dataset derived from the ChEMBL Legacy Malaria corpus for Malaria virtual screening, and conduct a systematic evaluation of five open-source LLMs; Gemma-2 2B/9B, TxGemma-2B/9B, and LlaSMol-Mistral-7B, on a rigorous out-of-distribution data split. Performance was benchmarked against classical ML models (Random Forest, XGBoost) and frontier proprietary models (Gemini 2.5, OpenAI o3) under few-shot conditions. Fine-tuned LLMs substantially outperformed all baselines: TxGemma-9B achieved the highest ROC-AUC ($0.731 \pm 0.005$) and LlaSMol-Mistral-7B the best enrichment factor (EF@1\% $\approx$ 4.99). Domain-specific fine-tuning proved categorically indispensable with TxGemma-9B collapsing from ROC-AUC 0.731 to 0.499, under its best few-shot condition, and neither Gemini 2.5 (ROC-AUC $\approx$ 0.53) nor o3 (ROC-AUC $\approx$ 0.59) achieved reliable discrimination without fine-tuning. Biomedical pretraining conferred a measurable advantage at equivalent scale, while chemistry-aware pretraining yielded superior prospective enrichment. Fine-tuned open-source LLMs represent a compelling, resource-efficient paradigm for antimalarial VS, outperforming both classical pipelines and proprietary reasoning models under structurally challenging conditions.

0.44

El Agente Fármaco: A Scalable AI Scientist for Drug Discovery

cs.AI cs.MAq-bio.BM ·2026-11-02 ·Marcel Müller, Mohammad Ghazi Vakili, Yoshihiro Ogura, Ella Ashoori, Shimeng Wang +11 more
benchmark similarity 0.61
Abstract · 63 pages, 13 figures, including Supporting Information

Computational drug discovery offers a growing range of tools for proposing and evaluating molecules, but combining them and deciding what to do next still requires substantial expert effort. Here, we introduce El Agente Fármaco, an AI scientist that uses modern large language model (LLM) technology to turn discovery goals expressed in everyday language into complex, scalable computational screening workflows. The agentic harness selects scientific tools, reviews their results, and adjusts subsequent steps to the target and the user's objectives. Our approach centers on a shared scientific memory: Fármaco Atlas, which stores molecules, structures, and results together with their provenance -- a record of how they were obtained. The agent uses targeted database queries to retrieve the evidence needed for each decision. A single request can launch calculations for an entire collection of molecules, without requiring a separate LLM decision for every compound. This design limits the information the model must process as screening collections grow, while keeping the underlying results available for inspection and further analysis. The integrated tools support molecule generation, prediction of binding and molecular properties, and searches for compounds available for purchase. In a retrospective comparison with an expert-led campaign, the agent proposed chemically distinct candidates with competitive docking scores and higher calculated drug-likeness under explicitly imposed selection criteria. In a 22-task benchmark against plain tool calls and Codex, the agent achieved the highest observed mean model-judged score, with lower median cumulative token use and peak context. Fármaco provides a foundation for flexible, scalable drug discovery workflows that connect scientific reasoning with an enduring, traceable record of computational work.

0.08

OpenMTB-Audit: Exposing Over-Refusal and Clinical Expert Perspectives in LLM-Based Molecular Tumor Board Safety Evaluation

cs.AI cs.LG ·2026-10-01 ·Negin Ashrafi, Jia Luo, Stacey M. Frumm, Roxana Daneshjou
publishedbenchmarkcode/data similarity 0.61
Abstract · Accepted for oral presentation and publication at the Pacific Symposium on Biocomputing (PSB) 2027

Molecular tumor boards integrate genomic findings, clinical context, and therapeutic evidence to support precision oncology. As AI enters this workflow, a key safety challenge is distinguishing truly unsupported recommendations from evidence-supported options that still require oncologist review because of incomplete information, poor ECOG performance status, or other clinical caveats. We introduce OpenMTB-Audit, an open-source benchmark of 500 synthetic non-small cell lung cancer cases spanning five adversarial error categories and four safety labels: Supported, Partially Supported, Unsupported, and Insufficient Information. Across eight large language model configurations, we identify pervasive over-refusal: all LLM configurations failed to retain the Partially Supported label in 83.3-100% of true Partially Supported cases, achieving high aggregate safety scores through label collapse rather than clinically calibrated reasoning. To address this limitation, we developed MTB-AuditAgent, a deterministic seven-module framework separating evidence verification, missing-information detection, safety classification, and abstention. It reduces over-refusal to 6.7% and achieves 91.2% accuracy (95% CI: 88.6-93.6%). A two-oncologist annotation study found disagreement concentrated at the boundary between information sufficiency and treatment optimization, underscoring the need to preserve clinically meaningful distinctions.

0.35